KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Equity Ratio (2016 - 2025)

Historic Equity Ratio for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to 0.85.

  • CRISPR Therapeutics AG's Equity Ratio fell 155.05% to 0.85 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.85, marking a year-over-year decrease of 155.05%. This contributed to the annual value of 0.85 for FY2025, which is 155.05% down from last year.
  • According to the latest figures from Q4 2025, CRISPR Therapeutics AG's Equity Ratio is 0.85, which was down 155.05% from 0.85 recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Equity Ratio ranged from a high of 0.92 in Q1 2021 and a low of 0.83 during Q1 2023
  • In the last 5 years, CRISPR Therapeutics AG's Equity Ratio had a median value of 0.85 in 2022 and averaged 0.85.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Equity Ratio surged by 482.91% in 2021, and later crashed by 676.86% in 2022.
  • Over the past 5 years, CRISPR Therapeutics AG's Equity Ratio (Quarter) stood at 0.87 in 2021, then fell by 4.11% to 0.84 in 2022, then increased by 1.0% to 0.84 in 2023, then increased by 2.05% to 0.86 in 2024, then fell by 1.55% to 0.85 in 2025.
  • Its Equity Ratio was 0.85 in Q4 2025, compared to 0.85 in Q3 2025 and 0.84 in Q2 2025.